Biomarkers are biological indicators of early disease detection (diagnostic), disease progression and outcome (prognostic), and response to therapy (predictive).
Tumor cells employ a variety of different strategies to evade the host immune attack. The immune reactivity of a tumor is a measure of its inflammatory state, which is determined by a combination of tumor-intrinsic and host-derived factors.
Mr. Nemzek has held executive senior leadership team positions in both public companies and a number of private companies that have become successful public companies by merger and acquisition.
The remarkable success of checkpoint control inhibitors in treating a variety of different cancers has necessitated a deeper assessment of the tumor and its microenvironment at the genetic and phenotypic level. Data from recent clinical trials has unequivocally established that the tumor microenvironment significantly impacts the efficacy of immune-oncology drugs.
This arrangement seamlessly integrates MedGenome’s cancer immunotherapy genomics platform with ZellNet’s immune monitoring services. This partnership will facilitate present customers of ZellNet’s immune monitoring services to quickly expand their cancer immunotherapy research into the genomics space by leveraging the power of next-generation sequencing-based approaches of neo-antigen and neo-epitope prediction.
A deep understanding of human genetic variation is essential for investigating the relationship between genotype and phenotype. The genetic sequence variations in individuals from different groups in South Asia is still not extensively explored.
MedGenome recently announced that its proprietary OncoPeptTOPE™ database of neo-antigens and neo-epitopes derived from genetic alterations using TCGA data will be made freely accessible to researchers in the cancer immunotherapy space.
The study titled “Whole Genome Sequencing data from the Wellderley study identifies rare variants in genes associated with diabetes and cardiomyopathy” involved the analysis of publicly available whole genome sequence data (WGS) of 454 healthy elderly Caucasian individuals (median age 85 years) from the Wellderly study.
Not too far in the future, you may be able to receive tailor-made medical treatment for your body, increasing your chances of survival and recovery from serious illnesses.
This is one of the aims of an initiative to sequence the genomes of 100,000 Asians over the next three to four years. The move will try to reduce the bias of modern medicine towards Western populations.
OncoMD Cancer Analytics Platform combines tumor mutation profiles, expression signatures, copy number variations, epigenetic alterations and drug sensitivity to create a holistic view of human cancer enabling discovery of new targets for therapy and prognosis.